Despite tremendous advances in treatments for myeloma in the past decade, the disease remains incurable in the majority of patients. Here, we review recent data demonstrating an association between obesity and increased risk of myeloma development. This may be due to the pro-inflammatory cytokine profile caused by obesity. Currently, there are no screening or prevention strategies for myeloma, but we propose that obesity-associated inflammatory pathways, or obesity itself, may be amenable to intervention, thereby preventing the transition from pre-malignancy to myeloma. In addition, we suggest that the morbidity, mortality and the significant costs associated with myeloma treatment could be reduced by addressing modifiable risk factors, and that research efforts should explore this novel hypothesis.
INTRODUCTION
Over the past several decades, the prevalence of obesity has increased markedly in the United States. 1 Today, two-thirds of the adult population in the United States is overweight (defined as body mass index (BMI) = 25 kg/m 2 and o 30 kg/m 2 ) or obese (BMI 30 kg/m 2 ). 2 A BMI greater than 25 kg/m 2 is associated with increased all-cause mortality. 3, 4 This increased risk exists even in the absence of typically-measured metabolic abnormalities, suggesting that there is no 'benign phenotype' for obesity. 5 A substantial number of these premature obesity-related deaths is due to cancer. 6, 7 Although the common solid tumor malignancies have received much attention, data from case-control and prospectively followed cohort studies have also demonstrated a positive association between obesity and plasma cell myeloma incidence and death. 7, 8 
RATIONALE FOR CONSIDERING A ROLE FOR OBESITY IN MYELOMA TREATMENT AND PREVENTION
Myeloma is the second most common hematologic malignancy in the United States with over 22 000 new diagnoses annually. 9 Nearly all patients progress to myeloma from the pre-malignant MGUS stage. 10 This asymptomatic pre-malignancy is present in 3% adults >50 years of age 11 and 1% of these MGUS cases progress to malignancy per year. 12 There are several unique attributes of myeloma that make investigation of the association between obesity and myeloma of particular interest.
(1) With current standard-of-care therapies, myeloma remains a terminal disease from the day of diagnosis. (2) Although there are a number of factors associated with increased risk of myeloma (e.g., race, sex, age), 13 obesity is the only known risk factor that is potentially modifiable.
14 Thus, obesity is currently the only identified risk factor whose modification has the potential to decrease population-level myeloma disease burden. (3) As patients who ultimately develop myeloma progress through the MGUS stage, 10 it is possible that screening and early identification of MGUS patients would allow intervention to prevent the progression of MGUS to myeloma. 15 (4) For most malignancies, elevated BMI increases cancer-specific death either through increased cancer incidence, decreased survival after diagnosis or both. 7 However, as myeloma is almost always fatal, decreasing the incidence of myeloma remains the only potentially significant mechanism to decrease mortality. This suggests that, if there is a relationship between obesity and the incidence of myeloma, obesity prevention or treatment measures would be an effective approach to reducing disease burden and mortality.
Thus, the goal of this review is to establish the link between obesity and myeloma, discuss the potential mechanisms whereby obesity may increase the incidence of myeloma, and provide an overview of how obesity may modify treatment and prognosis. Finally, we discuss several areas where future investigation may be warranted.
EPIDEMIOLOGICAL EVIDENCE LINKING OBESITY TO MGUS INCIDENCE AND PROGRESSION TO MYELOMA
Obesity is the quantifiable end result of an energy imbalance, with body mass and composition determined primarily by energy input (diet) and expenditure (physical activity). However, both diet and physical activity may have independent physiological effects that influence health outcomes, 16, 17 including cancer incidence, [18] [19] [20] [21] independent of body composition. We begin with a global discussion of the role of body size in modifying disease risk and then independently consider the influences of diet and exercise.
The link between obesity and the incidence of myeloma The highest quality data evaluating the relationship between myeloma and BMI comes from prospective cohort studies. These studies are summarized in Table 1 , and universally suggest a role for increased body mass in increasing myeloma risk in both men and women. In one of the landmark prospective cohort studies performed in the United States, including over 900 000 men and women with a mean follow-up of 16 years, a significantly increased relative risk of myeloma death (relative risk = 1.44 (95% confidence interval (CI) = 1.10-1.89) in men and 1.47 (95% CI = 1.12-1.97) in women) was noted in patients with BMI of 30-34.9 kg/m 2 . 7 Whether there is a dose-response relationship between body size and myeloma risk is less clear. A meta-analysis of 10 prospective cohort studies, cumulatively containing 5.1 million men and women with a mean follow-up of 14.6 years, demonstrates an increase in the incidence of myeloma (relative risk = 1.11) in men and women for each increase in BMI of 5 kg/m 2 over 25 kg/m 2 . 22 On the other hand, another meta-analysis of 15 cohort studies of myeloma incidence and 5 studies of myeloma mortality demonstrates similar risk estimates for overweight men and women (BMI = 25 and o30 kg/m 2 ) (relative risk = 1.12 (95% CI = 1.07-1.18)) and obese men and women (BMI = 30 kg/m 2 ) (relative risk = 1.21 (95% CI = 1.08-1.35)). 8 The timing or duration of obesity may also influence the incidence of cancer. 35 Birmann et al. evaluated self-reported weights of women enrolled in the Nurses' Health Study. 36 Somatograms were also used to estimate body shape at ages 5, 10, 20, 30 and 40 years of age. These authors noted a trend toward increased risk of myeloma in those reporting heavier body shapes in childhood (ages 5 and 10, 95% CI = 0.8-4.2) and adolescence (ages 10 and 20; 95% CI = 0.6-4.1) compared with those reporting lean body shapes, suggesting that adiposity in childhood may modify risk. Because being overweight during childhood predicts obesity during adulthood, 37 it is possible that childhood obesity is simply a surrogate for obesity later in life. It is also possible that an increased duration of obesity or obesity during critical life stages translates into increased risk. It remains to be confirmed if the timing (childhood, adolescence or adult) or duration of obesity exposure most influence the incidence of myeloma.
As with most epidemiological studies evaluating the role of obesity in disease development, these studies have important limitations. The majority of large cohort studies rely on selfreporting. Although self-reported height and weight is generally accurate, it may be less reliable in particular subpopulations including individuals o 45 years of age and the overweight and obese. There are also reporting differences between black and white men and a tendency toward end-digit bias among all patients, with values ending in '0' or '5' most frequently reported. 38 Furthermore, BMI fails to account for differences in body shape or fat composition which, beyond overall composition, may have an additional impact on disease risk. 39, 40 Link between obesity and the transition from MGUS to myeloma As MGUS is an asymptomatic condition that is not routinely screened for, it is not easy to determine how obesity influences the incidence of MGUS. The best indirect evidence comes from a cross-sectional study of white and black women (40-70 years) in which obesity was associated with a significantly increased risk of MGUS (OR = 1.8; 95% CI = 1.03-3.1).
Whether or not obesity influences the progression of MGUS to myeloma also remains unanswered, although a small case-control study performed on 100 MGUS patients who progressed to myeloma and 100 controls with MGUS who were matched by age, gender and year of diagnosis demonstrated no significant association between obesity and risk of progression to myeloma. 41 Given the small size of this case-control study and lack of information on known risk factors for MGUS progression, it is difficult to discern if the lack of association is due to absence of association vs lack of power vs heterogeneous baseline characteristics. Understanding the association between obesity and progression of MGUS thus represents a significant area of knowledge deficit. In the presence of a positive association it would represent an ideal time for implementation of a weight loss intervention to reduce the risk of transformation to myeloma. Impact of diet on the incidence of myeloma The quality of the evidence supporting an independent influence of dietary habits on myeloma incidence and survival is lower than that supporting such a link to obesity and is limited to case-control studies which are subject to recall bias. Reduced odds of myeloma development are associated with higher consumption of cruciferous vegetables (OR = 0.7, 95% CI = 0.5-0.99) and fish (OR = 0.7, 95% CI = 0.5-0.9). 42 Both of these findings were confirmed in a smaller case-control study. 43 The protective association seen between high fish consumption and reduced myeloma incidence was further supported by a study that demonstrated decreased odds of the development of leukemia, Abbreviations: BMI = body mass index; CI = confidence interval.
Obesity and plasma cell myeloma KR Carson et al myeloma and non-Hodgkin lymphoma (NHL) in those consuming more fish. 44 In the same studies, the evidence supporting that high-risk dietary habits may predispose individuals to myeloma was less consistent. Although there was a suggestion of a weak association between dairy products and animal fats in one study, these findings did not reach statistical significance.
When interpreting these studies, it is important to point out the known inverse association between obesity and fruit/vegetable intake. 45 Patients who eat more vegetables are less likely to be obese, making it possible that some of the observed difference due to obesity in prospective cohort studies may actually be confounded by dietary choices. Impact of exercise on the incidence of myeloma Although increased physical activity has been associated with a protective effect in some types of cancer, 46 Birmann et al. 14 found no association between the amount of time spent in vigorous activity each week and incidence of myeloma in men. In women, point estimates suggest a trend toward decreased risk of myeloma in those with >2 h/week of exercise. In a large prospective cohort study by Walter et al., 47 following over 65 000 men and women in whom there were 666 incident cases of hematologic malignancy (including 80 plasma cell dyscrasias), regular physical activity had no significant association with the risk of myeloma. Consistent findings were seen in a recent meta-analysis evaluating the association between physical activity and risk of Hodgkin lymphoma and NHL, in which no significant association was demonstrated. 48 Overall, these findings suggest that physical activity alone has little impact on myeloma incidence.
It should be noted that these are not randomized, controlled studies and, again, rely primarily on self-reporting. It is possible that, as with other diseases, the timing of the initiation of exercise training, type of training, duration and frequency of exercise are important in modifying myeloma risk 49 and that benefits would be observed with controlled training interventions. Exercise also directly modifies the expression of growth factors 50 and inflammatory mediators 51, 52 that may be potential therapeutic targets in preventing MGUS to myeloma progression. Yet, there is no conclusive evidence that exercise training without caloric restriction has any appreciable impact on weight loss 53, 54 and may even result in weight gain. If adiposity is required for increased myeloma risk, exercise alone as an intervention is unlikely to be effective.
PHYSIOLOGICAL PATHWAYS LINKING OBESITY AND MYELOMA
Myeloma is a malignancy of terminally differentiated B-lymphocytes. Ninety percent NHL is also of B-cell origin with numerous studies demonstrating a significant association between obesity and the risk of NHL incidence and death, 7, 22 Because obesity increases the risk of both NHL and myeloma, this suggests that obesity may influence oncogenesis at multiple points in the pathway of B-cell differentiation (Figure 1) . Table 2 shows hormones and cytokines of interest in the relationship between obesity and myeloma. Adipokines Adiponectin. Adiponectin was discovered as the most highly abundant transcript expressed in adipocytes, with serum levels decreased in obese individuals. 55 Low adiponectin levels mediate several obesity-related complications including the metabolic syndrome, 56 and normal levels may also be protective in several cancer types including myeloma. [57] [58] [59] In vitro studies have shown that adiponectin decreases cellular proliferation and increases apoptosis. 60 Thus, obesity-induced suppression of adiponectin levels may be critical in the development of myeloma.
Adiponectin levels are also dimorphic, with higher levels in women than in men, 61 which may help explain the increased incidence of myeloma in men. Although obesity is associated with elevation in other inflammatory cytokines, 62 adiponectin may have a major role in myelomagenesis, a role that is currently under investigation. In light of consistent evidence supporting an inverse association between adiponectin and myeloma incidence, adiponectin receptor agonists will almost certainly be studied in the pre-clinical setting to determine if clinical trials may be indicated.
Leptin. Leptin is secreted by adipocytes and is involved in the regulation of energy homeostasis and metabolism. 63 Serum levels of leptin correlate with obesity and the percentage of body fat, whereas weight loss is associated with decreased levels of leptin. 64 Research in solid tumor malignancies has suggested that higher serum leptin levels may be associated with higher disease stage and grade, potentially due to off-target effects of leptin that enhance oncogenesis via numerous intracellular pathways. 65, 66 Studies have not demonstrated a consistent association between leptin and myeloma. One study found higher serum leptin levels in patients with myeloma compared with controls. 67 Another confirmed those results and additionally reported in vitro work that suggests that leptin induces changes in gene expression that enhance myeloma cell growth and viability. 68 Conversely, two studies found no relationship between leptin and myeloma. 57, 58 Taken together, these studies suggest an unclear role for leptin in the progression of myeloma and more investigation will be required.
Growth factors and cytokines
Insulin and Insulin-like growth factors. The insulin-like growth factor (IGF) system is made up of a family of ligands (IGF-I and IGF-II), binding proteins (IGFBP 1-6), and receptors (IGF-IR and IGF-IIR) and is associated with cancer cell growth and survival. Increased levels of IGF-I and IGF-II are associated with an increased risk of a number of different malignancies, and IGF-I receptors are expressed on many tumor cell types. 69 There is a well-known positive association between BMI, insulin resistance and circulating insulin levels. 70 In turn, increased insulin levels are associated with decreased levels of insulin-like growth factor binding protein-1, which inhibits the activity of insulin-like growth factor-1. 71 Numerous pre-clinical studies have demonstrated that IGF-I is a potent mitogen in myeloma cell lines. 72, 73 There is also evidence suggesting that due to the sequence homology between insulin and IGF-I, insulin itself may activate the IGF-IR at physiologic insulin concentrations. Although early data suggested that the IGF system may represent a promising therapeutic target for the treatment of myeloma, 75, 76 results of clinical trials of novel IGF receptor inhibitors have been disappointing, suggesting alternate pathways for cell cycle activation develop in the setting of IGF-IR inhibition. 77 A case-control study evaluating IGF-I levels in patients with and without myeloma demonstrated that myeloma patients did not have higher IGF-I levels. However, in the same study, higher IGF-I levels were associated with poorer myeloma survival. 78 Given the relationship between insulin and IGF, it is also important to point out a meta-analysis of studies looking at the association between type 2 diabetes mellitus and myeloma demonstrated nonsignificant increased odds of myeloma in patients with type 2 diabetes mellitus (odds-ratio = 1.22, 95% CI = 0.98-1.53). 79 Whether insulin and IGF are involved in the transition from MGUS to myeloma is a topic worthy of further exploration. A recent study by Birmann et al. suggests a complex relationship between insulin, IGF and myeloma incidence, if one exists. Contrary to the a priori expectations of the authors, they found no relationship between IGF-I, insulin and myeloma risk. 80 As this study utilized serum samples collected prospectively, before myeloma diagnosis, it suggests that therapeutic intervention against insulin or an insulin-like growth factor may be less attractive than previously thought.
Interleukin-6 (IL-6).
The cytokine IL-6 is secreted by adipocytes, and serum levels of IL-6 correlate with BMI. 81 IL-6 is critical in multiple facets of the myeloma disease process. First, IL-6 is an important in vivo and in vitro growth factor in myeloma. 82 Second, IL-6 has demonstrated inhibition of dexamethasone-induced apoptosis in myeloma tumor cells. 83 Third, IL-6 may be an important factor in the promotion of myeloma bone disease. Although obesity is associated with increased IL-6 levels, it is important to point out that in patients with active myeloma there is potent paracrine secretion of IL-6, likely reducing the importance of adipocyte derived IL-6. Results from a clinical study evaluating a MoAb inhibitor of IL-6 in patients with myeloma were disappointing, 84 though therapeutic approaches targeting IL-6 remain an area of active inquiry. 85 Recently, Birmann et al.
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demonstrated an association between soluble IL-6 receptor levels and myeloma incidence, supporting the relevance of the IL-6 pathway. Although previous trials in patients with myeloma were negative, it is possible that there could be a role for IL-6 inhibition in a prevention setting.
IMPACT OF OBESITY ON MYELOMA TREATMENT AND PROGNOSIS
Obesity and hematopoetic cell transplantation The role of obesity on drug dosing in patients receiving high-dose melphalan and autologous hematopoietic cell transplantation has also been studied. Although obesity would be expected to inflate chemotherapy doses through calculations of body surface area, many transplant centers base chemotherapy doses on adjusted or ideal body weight. 86 Furthermore, even without weight adjustments in obese patients, body surface area calculations reduce the impact of weight on the chemotherapy dose. 87 One study of patients receiving autologous transplantation for a variety of diseases suggested that there was no significant difference in outcomes when the dose was adjusted for ideal body weight. 86 Similarly, obesity had no significant effect on progression free or OS for patients with myeloma receiving autologous transplantation with common chemotherapy dosing regimens. 88 This occurred despite the fact that dose reduction strategies were more common in the obese patients. In this study, superior outcomes were noted in the subgroup of obese myeloma patients who were treated with melphalan and TBI conditioning, though the clinical significance of this finding is unclear. Although guidelines from the American Society of Clinical Oncology state that patients should receive cytotoxic chemotherapy doses on the basis of actual body weight, the accompanying literature review did not specifically evaluate patients receiving hematopoietic cell transplantation, limiting the ability to extrapolate to the transplant setting. 89 The role of allogeneic transplantation in myeloma patients remains under investigation, 90, 91 but it is likely that fewer obese patients will be offered this procedure compared with normal weight patients. First, obese individuals tend to have more cardiovascular and other comorbidities, increasing risk of early mortality after transplant. 92 Second, obesity itself is considered an independent comorbidity in a tool frequently used to assess comorbidity in transplant patients. 93 Third, with the increased use of umbilical cord blood transplantation, achieving an adequate stem cell dose for obese patients remains a challenge. 94 Although there are conflicting data surrounding the independent influence of obesity on allogeneic transplantation outcomes, [95] [96] [97] retrospective studies in this area are limited to some degree by selection bias and likely underestimate an adverse effect of obesity on outcomes. Overall, it is likely that obesity will limit the application of allogeneic transplant, should the use of this treatment modality become routine in patients with myeloma.
Body mass and survival after myeloma diagnosis Although the most important influence of obesity on myeloma outcomes is the association with increased incidence, obesity may also influence survival after diagnosis. In a cohort of United States Veterans with myeloma, we found that patients who were obese at the time of diagnosis had improved survival compared with those who were normal or underweight. 98 Part of this observation is attributable to disease-related weight loss in the months leading up to the diagnosis, which predicted worse survival. Patients with disease-related weight loss were then more likely to be normal or underweight at the time of diagnosis, even if they were obese previously. Therefore, although obesity increases the risk of developing myeloma, obesity appears 'protective' at the time of myeloma diagnosis probably because weight loss ensues with the onset of aggressive disease. in the large majority of patients. Therefore we propose that an additional focus should be on the prevention of myeloma, which would effectively 'cure' a number of patients through prevention. Using pre-clinicaI models and additional observational studies, the first step will be to determine if obesity is driving only the development of MGUS or if it influences the transition from MGUS to myeloma. If obesity is only impacting the development of MGUS, prevention would require population-level interventions to reduce the overall incidence of obesity. The difficulty with this approach is that despite public health efforts in this area and widespread public awareness of the dangers of obesity, this remains a complex problem 99 and the prevalence of obesity has not declined in the United States. 2 Furthermore, a slight reduction in the risk of a rare disease like myeloma is unlikely to be a major driver of health behavior in the population. Instead, it will merely represent yet another reason why being overweight or obese is unhealthy.
On the other hand, if obesity has a strong influence on the transition from MGUS to myeloma, then a major shift in thinking about the management of MGUS may be in order to prevent myeloma. As obesity is modifiable, it would suggest that weight reduction in MGUS patients would reduce the incidence of myeloma and should be considered in all with MGUS. This provides rationale for MGUS screening, so that MGUS patients could be identified and weight loss interventions initiated early in those individuals who are overweight or obese.
It is unclear, however, what the most effective intervention strategy would be. Overweight and obese MGUS patients could be enrolled in medically monitored diet and exercise programs as an initial intervention to reduce the risk of myeloma. Weight management programs are covered by many health insurance plans, carry little inherent risk and public support for these types of interventions is high. 100 A substantial number of these patients would not achieve sufficient weight loss, despite diet and exercise instruction, translating to a large investment with little change in population risk. 101 Alternatively, bariatric surgery could be considered for those who do not have success with behavioral modification therapy. Although the cost of bariatric surgery is considerable, those expenses may be offset by the reduced downstream costs associated with myeloma treatment, treatment of other obesity-related diseases and increased longevity. 102 Ultimately, a finding that obesity drives the transition of MGUS to myeloma might even warrant a change in the name of MGUS to something along the lines of pre-myeloma. If interventions are warranted in patients with disease that we currently consider 'of undetermined significance,' there is clear significance of this finding.
Similarly, with better understanding of how obesity increases myeloma risk, pharmacologic interventions could be developed for myeloma prevention in MGUS patients. Until recently, there was no evidence that treating myeloma early in the disease process had significant benefits, but it now appears that patients with smoldering myeloma, an intermediate stage of disease between MGUS and active myeloma with end-organ damage, have better outcomes with early treatment. Mateos et al. 103 demonstrated that treatment of high-risk smoldering myeloma reduces the risk of progression to myeloma and improves OS. 103 This supports the notion that earlier intervention alters the progression of high-risk smoldering myeloma, and perhaps such a benefit will extend treatment of high-risk MGUS patients with treatment. Although patients with high-risk smoldering myeloma benefitted from the immunomodulatory agent lenalidomide and dexamethasone, it is worth considering if less costly interventions may benefit patients with high-risk MGUS. For example, the use of generic pharmaceuticals that inhibit various aspects of the hormone and cytokine pathways impacted by obesity might provide a cost-effective way to reduce risk of progression to myeloma. For example, recent evidence suggests that higher aspirin intake is associated with reduced risk of myeloma. 104 Metformin has demonstrated improvements in survival in diabetic patients with other malignancies, [105] [106] [107] and would be a logical candidate for chemoprevention of myeloma as well.
Much like the situation with the timing of measures to address obesity, before pharmacologic interventions are embraced, it will be critical to understand if putative preventative agents reduce the risk of MGUS development or the transition of MGUS to myeloma. Only reductions in the progression of MGUS to myeloma would warrant screening or changes in the management of MGUS, whereas prevention of MGUS formation would be complicated by a relatively low incidence and low risk of transformation to myeloma requiring treatment of 100s of people for every case of myeloma prevented. Positive findings from any study that supports intervention in patients with MGUS would represent a major paradigm shift in the thinking about MGUS. As all patients develop MGUS before myeloma, an effective MGUS intervention would provide rationale for routine screening of the older population to detect what is typically considered an incidental laboratory finding.
CONCLUSIONS
The epidemiologic evidence supporting a positive association between obesity and myeloma incidence is clear. The significance of this finding is that reducing disease incidence might be a way to reduce the number of deaths due to myeloma, through prevention. At this time, obesity remains the only known modifiable risk factor for the development of myeloma. Although our current understanding of the association between obesity and myeloma leaves many unanswered questions, the prospect that myeloma deaths may be reduced through prevention strategies as opposed to disease treatment strategies, supports further research efforts in this area.
